The EESC issues between 160 and 190 opinions and information reports a year.
It also organises several annual initiatives and events with a focus on civil society and citizens’ participation such as the Civil Society Prize, the Civil Society Days, the Your Europe, Your Say youth plenary and the ECI Day.
The EESC brings together representatives from all areas of organised civil society, who give their independent advice on EU policies and legislation. The EESC's326 Members are organised into three groups: Employers, Workers and Various Interests.
The EESC has six sections, specialising in concrete topics of relevance to the citizens of the European Union, ranging from social to economic affairs, energy, environment, external relations or the internal market.
welcomes the European Commission's proposal and supports the initiative to ensure that clinical trials with medicinal products that contain or consist of GMOs and are intended to treat or prevent COVID-19 can start asspeedily as possible;
believes it is of utmost importance that such clinical trials ensure the rights, safety, dignity and well-being of those individuals taking part, the reliability and robustness of the data generated, and adequate protection of human health and of the environment;
agrees that the development of vaccines and therapies against COVID-19is of major relevance to the public. However, additional measures are required to ensure optimal immunisation;
considers that the development of vaccines in general and the proposed Regulation in particular should go hand in hand with the EU vaccines strategy for COVID-19 vaccines but also with an EU vaccination strategy as outlined in the comments made in the present opinion;
recommends that the Commission develop "Good Simulation Practices" so that industries have a definite regulatory framework within which to act when deploying computer modelling and simulation solutions in healthcare and in particular, in pre-clinical activity and in clinical trials, which is even more critical in times of public health emergency such as the COVID-19 pandemic;
considers that the pharmaceutical and medical device industries should be encouraged to present real-time data to the authorities on a day-to-day basis to ensure the prompt development of therapies against COVID-19.